1. Home
  2. GKOS vs HASI Comparison

GKOS vs HASI Comparison

Compare GKOS & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$114.27

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Logo Hannon Armstrong Sustainable Infrastructure Capital Inc.

HASI

Hannon Armstrong Sustainable Infrastructure Capital Inc.

HOLD

Current Price

$32.77

Market Cap

4.2B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
HASI
Founded
1998
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
4.2B
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
GKOS
HASI
Price
$114.27
$32.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
8
Target Price
$123.62
$39.88
AVG Volume (30 Days)
860.2K
1.1M
Earning Date
10-29-2025
11-06-2025
Dividend Yield
N/A
5.11%
EPS Growth
N/A
27.54
EPS
N/A
2.32
Revenue
$469,820,000.00
$99,644,000.00
Revenue This Year
$31.15
$187.33
Revenue Next Year
$24.15
$16.20
P/E Ratio
N/A
$14.21
Revenue Growth
30.38
N/A
52 Week Low
$73.16
$21.98
52 Week High
$163.71
$34.54

Technical Indicators

Market Signals
Indicator
GKOS
HASI
Relative Strength Index (RSI) 77.10 52.00
Support Level $105.88 $32.41
Resistance Level $110.87 $33.38
Average True Range (ATR) 3.08 0.68
MACD 0.12 -0.22
Stochastic Oscillator 95.36 16.94

Price Performance

Historical Comparison
GKOS
HASI

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.

HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.

Share on Social Networks: